In a murine K-RAS-driven lung cancer model designed to reversibly inhibit c-MYC, c-MYC inhibition not only induced regression of incipient and established lung tumors, it also exerted profound effects on normal regenerating tissues, as might be anticipated. This evidence concerns the gene KRAS and lung carcinoma.